Quick Answer
Black Diamond Therapeutics, Inc. reported Stockholders Equity of $112.21 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +34.7% in Stockholders Equity from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$19.28 million | Q2 2019: -$31.37 million | Q3 2019: -$39.79 million | Q1 2020: $355.27 million | Q2 2020: $343.13 million | Q3 2020: $327.35 million | Q1 2021: $280.75 million | Q2 2021: $251.02 million | Q3 2021: $218.95 million | Q1 2022: $172.56 million | Q2 2022: $152.37 million | Q3 2022: $133.23 million | Q1 2023: $98.19 million | Q2 2023: $82.20 million | Q3 2023: $134.32 million | Q1 2024: $104.31 million | Q2 2024: $110.52 million | Q3 2024: $97.43 million | Q1 2025: $141.52 million | Q2 2025: $132.61 million | Q3 2025: $126.15 million.
- Over the full 9 years of available data (2017 to 2025), Black Diamond Therapeutics, Inc.'s Stockholders Equity has grown by 1,781.1%.
- Historical annual values: Fiscal year 2025: $112.21 million | Fiscal year 2024: $83.29 million | Fiscal year 2023: $116.74 million | Fiscal year 2022: $115.70 million | Fiscal year 2021: $195.90 million | Fiscal year 2020: $307.76 million | Fiscal year 2019: -$47.16 million | Fiscal year 2018: -$15.54 million | Fiscal year 2017: -$6.68 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: